News

On April 24-25, 2025, the annual Scientific and Practical Conference with international participation "Current issues of preserving somatic and reproductive health of women" was held (Ukraine, Kyiv). This scientific and educational event annually brings together more than 1,500 participants.

The conference program included speeches by top speakers on the most relevant topics of obstetrics, gynecology and reproductology. The brightest and most charismatic stars of domestic obstetrics, gynecology and reproductology and doctors from other countries took part in one event. The leading gynecological schools of Ukraine were presented at the conference - the cities of Kyiv, Dnipro, Kryvyi Rih, Kharkiv, Odessa, Lviv, Poltava, Uzhgorod, Vinnytsia, Ternopil.

In his report "Infection with herpesvirus and papillomavirus in women of fertile age and modern treatment options", Professor, Doctor of Medical Sciences, Head of the Department of "Health Problems of Women of Fertile Age" Research Institute of Paediatrics of the Academy of Medical Sciences of Ukraine Podolsky Vasyl Vasilyevich drew attention to the relevance of the problem of diseases of the genital organs and the experience of using interferon alpha-2b ALFAREKIN in the complex therapy of the most common gynecological pathologies. In Ukraine, inflammatory diseases occur in 30-35% of women of reproductive age. An important role in the etiology of inflammatory diseases of the genital organs is assigned to the genital herpes virus.

In the first place in the algorithm for the treatment of urogenital herpes is etiotropic treatment with antiviral drugs. The department used the drug ALFAREKIN for the treatment of inflammatory processes of the genital organs. The drug affected the genital herpes virus and all strains of HPV (high, medium and low oncogenic risk).

Particular attention was focused on the relevance of the use of various forms of ALFAREKIN (injections and suppositories).

In the indicated pathology - it was ADVISABLE to use a "stepped" regimen of therapy suppositories + injections at a dose of 2 million IU intramuscularly.

The department's specialists noted the safety and high level of immunogenicity of ALFAREKIN due to the absence of albumin.